Contract with Customer, Asset, Net, Current - Not Material

No definition available.

Name:	revv_ContractWithCustomerAssetNetCurrentNotMaterial
Namespace Prefix:	revv_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Customer Deposits Received in Advance of Transfer of Control, Current

+ References

No definition available.

+ Details

Name:	revv_CustomerDepositsInAdvanceOfTransferOfControlCurrent
Namespace Prefix:	revv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Remaining Performance Obligations

+ References

No definition available.

+ Details

Name:	revv_RemainingPerformanceObligations
Namespace Prefix:	revv_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Unbilled Receivables

+ References

No definition available.

+ Details

Name:	revv_UnbilledReceivables
Namespace Prefix:	revv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- References

No definition available.

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_StatementGeographicalAxis=srt_AmericasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=srt_AsiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=revv_DiagnosticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=revv_LifeSciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	revv_MajorGoodsserviceLinesAxis=revv_LifeSciencesSolutionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	revv_MajorGoodsserviceLinesAxis=revv_SoftwareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	revv_MajorGoodsserviceLinesAxis=revv_ReproductiveHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	revv_MajorGoodsserviceLinesAxis=revv_AppliedGenomicsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	revv_MajorGoodsserviceLinesAxis=revv_ImmunodiagnosticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Revenue (Details) - USD ($) $ in Thousands	Jun. 29, 2025	Jun. 30, 2024	Jun. 29, 2025	Jun. 30, 2024	Dec. 29, 2024
Disaggregation of Revenue [Line Items]
Segment revenue	$ 720,284	$ 691,685	$ 1,385,046	$ 1,341,605
Unbilled Receivables	91,100		91,100		$ 80,600
Deferred Revenue	225,300		225,300		212,800
Customer Deposits in Advance of Transfer of Control, Current	$ 19,000		$ 19,000		$ 19,500
Remaining Performance Obligations			Transaction price allocated to the remaining performance obligationsThe Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.
Contract with Customer, Asset and Liability [Abstract]
Contract with Customer, Asset, Net, Current - Not Material	The Company had no material contract assets as of June 29, 2025 and December 29, 2024.
Americas [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	$ 323,580	307,783	$ 628,209	602,137
Europe [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	203,632	184,588	385,424	363,150
Asia [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	193,072	199,314	371,413	376,318
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	354,386	343,160	678,753	656,566
Diagnostics [Member] \| Americas [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	126,509	117,993	246,859	235,770
Diagnostics [Member] \| Europe [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	119,334	110,036	225,104	211,142
Diagnostics [Member] \| Asia [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	108,543	115,131	206,790	209,654
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	365,898	348,525	706,293	685,039
Life Sciences [Member] \| Americas [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	197,071	189,790	381,350	366,367
Life Sciences [Member] \| Europe [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	84,298	74,552	160,320	152,008
Life Sciences [Member] \| Asia [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	84,529	84,183	164,623	166,664
Life Sciences Solutions [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	298,052	297,782	584,505	589,394
Life Sciences Solutions [Member] \| Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	0	0	0	0
Life Sciences Solutions [Member] \| Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	298,052	297,782	584,505	589,394
Software [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	67,846	50,743	121,788	95,645
Software [Member] \| Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	0	0	0	0
Software [Member] \| Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	67,846	50,743	121,788	95,645
Reproductive health [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	135,568	129,908	262,373	254,653
Reproductive health [Member] \| Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	135,568	129,908	262,373	254,653
Reproductive health [Member] \| Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	0	0	0	0
Applied genomics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue		691,685		1,341,605
Immunodiagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	218,818	213,252	416,380	401,913
Immunodiagnostics [Member] \| Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	218,818	213,252	416,380	401,913
Immunodiagnostics [Member] \| Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	$ 0	$ 0	$ 0	$ 0